- Home
- Publications
- Publication Search
- Publication Details
Title
In-Depth Analysis Shows Synergy between Erlotinib and miR-34a
Authors
Keywords
-
Journal
PLoS One
Volume 9, Issue 2, Pages e89105
Publisher
Public Library of Science (PLoS)
Online
2014-02-15
DOI
10.1371/journal.pone.0089105
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- TP53-independent Function of miR-34a via HDAC1 and p21CIP1/WAF1
- (2013) Jane Zhao et al. MOLECULAR THERAPY
- MicroRNAs and other non-coding RNAs as targets for anticancer drug development
- (2013) Hui Ling et al. NATURE REVIEWS DRUG DISCOVERY
- An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
- (2012) L. A. Byers et al. CLINICAL CANCER RESEARCH
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- miR-34 – a microRNA replacement therapy is headed to the clinic
- (2012) Andreas G. Bader Frontiers in Genetics
- MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status
- (2011) Ruth L. Vinall et al. INTERNATIONAL JOURNAL OF CANCER
- Genome-wide Characterization ofmiR-34aInduced Changes in Protein and mRNA Expression by a Combined Pulsed SILAC and Microarray Analysis
- (2011) Markus Kaller et al. MOLECULAR & CELLULAR PROTEOMICS
- The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44
- (2011) Can Liu et al. NATURE MEDICINE
- Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer
- (2011) G Mudduluru et al. ONCOGENE
- Capture of MicroRNA–Bound mRNAs Identifies the Tumor Suppressor miR-34a as a Regulator of Growth Factor Signaling
- (2011) Ashish Lal et al. PLoS Genetics
- Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells
- (2010) Yukihiro Akao et al. CANCER LETTERS
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- The Promise of MicroRNA Replacement Therapy
- (2010) A. G. Bader et al. CANCER RESEARCH
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma
- (2010) Shyamal D. Weeraratne et al. NEURO-ONCOLOGY
- MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms
- (2010) Keitaro Kojima et al. PROSTATE
- PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
- (2009) M. L. Sos et al. CANCER RESEARCH
- High Expression Levels of Total IGF-1R and Sensitivity of NSCLC Cells In Vitro to an Anti-IGF-1R Antibody (R1507)
- (2009) Yixuan Gong et al. PLoS One
- Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells
- (2008) Yasunori Fujita et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres
- (2008) Qing Ji et al. BMC CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search